Compare Organon & Co. Common Stock (OGN) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Zillow Group Inc Class C — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Zillow Group Inc Class C trades at $28.41 (market cap $6.33B). The key difference: Zillow Group Inc Class C is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Zillow Group Inc Class C for 39 Days on average.
| OGN | Z | |
|---|---|---|
Market Cap | $3.62B | $6.33B |
Volume | 2,892,999 | 4,060,713 |
Sector | Health | Media |
52-Week High | $13.81 | $78.04 |
52-Week Low | $5.70 | $27.13 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $11.04B | $6.21B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Zillow Group (Z) trades at $27.97, showing modest daily gains but facing bearish technical signals with the current price near key support levels. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though valuation metrics remain elevated with a P/E of 121.57. Recent developments include AI integration initiatives and resolution of FTC litigation, while the housing market faces affordability challenges.
The stock presents a mixed outlook with analyst consensus pointing to significant upside potential (average target $52) but near-term headwinds from housing market volatility. Investment opportunity lies in Zillow's platform transition and market leadership, balanced against risks from mortgage rate sensitivity and competitive pressures. The current price near 52-week lows may offer entry points for long-term investors believing in the housing tech transformation story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
